Veradigm (MDRX) announced an advancement in the use of artificial intelligence to scale the generation of real-world evidence for GLP-1 receptor agonists, including semaglutide and tirzepatide. By applying AI to electronic health record deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights-such as side effects, discontinuation reasons, and social determinants of health-that traditionally required intensive manual curation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDRX: